898 abstracts found.



Results filter

Directing the clinical use of ATR inhibitors

Year:

Session type:

Chris Williamson1, Helen Pemberton1, Rachel Brough1, Richard Elliott1, Christopher Lord1, Alan Ashworth1,
1The Institute of Cancer Research, London, UK

The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey: a comparison of UK-based clinicians to clinicians in the EU and worldwide regarding adjuvant chemotherapy (AdjCT) treatment decisions for early stage HR+, HER2- breast cancer (BC) patients 

Year:

Session type:

Daniel Rea1, Matti Aapro2, Juan Enrique Bargallo Rocha3, Michele De Laurentiis4, László Landherr5, Barbro Linderholm6,16, Terry Mamounas7, Christos Markopoulos8, Miguel Martin9, Patrick Neven10, Alexander Petrovsky11, Roman Rouzier12, Vincent Smit13, Christer Svedman14, Christoph Thomssen15,
1University of Birmingham, Birmingham, UK,2Clinic of Genolier, Genolier, Switzerland,3Instituto Nacional de Cancerologia, Mexico City, Mexico,4National Cancer Institute G. Pascale Foundation, Naples, Italy,5Uzsoki Teaching Hospital, Budapest, Hungary,6Sahlgrenska Academy and University Hospital, Gothenburg, Sweden,7Orlando Health, Orlando, USA,8Athens University Medical School, Athens, Greece,9Hospital General Universitario Gregorio Marañón, Madrid, Spain,10UZ Leuven, Leuven, Belgium,11Russian Cancer Research Center, Moscow, Russia,12Institut Curie-Université Versailles-Saint-Quentin, Paris-Saint-Cloud, France,13Leiden University Medical Center, Leiden, The Netherlands,14Genomic Health, Stockholm, Sweden,SaaleMartin-Luther-University Halle-Wittenberg, Halle,16Karolinska University Hospital, Stockholm, Sweden

A Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 in patients with Advanced Malignancies Expressing the Biomarker HR23B

Year:

Session type:

Toby Eyre1, Avinash Gupta1, Nick Coupe1, Ioannis Karydis1, Semira Sheikh3, Graham Collins2, Nick La Thangue3, David Kerr3, Mark Middleton1,
1Early Phase Clinical Trials Unit, The Oxford Cancer Centre, Churchill Hospital, Oxford, UK,2Department of Clinical Haematology, The Oxford Cancer Centre, Churchill Hospital, Oxford, UK,3Laboratory of Cancer Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, UK

An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones

Year:

Session type:

Burcu Anil3, Elizabeth Blackburn3, Tim Blackburn1, Sarah Cully1, Junfeng Liu2, Karim Bennaceur2, Catherine Drummond2, Jane Endicott2,3, Bernard Golding1, Roger Griffin1, Karen Haggerty1, Xiaohong Lu2, John Lunec2, Herbie Newell2, Charlotte Reville1, Christiane Riedinger3, Anna Watson1, Yan Zhao2, Ian Hardcastle1, Martin Noble2,3,
1Newcastle Cancer Centre, School of Chemistry, Newcastle University, Newcastle upon Tyne, UK,2Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK,3Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, Oxford, UK

Patient and tumour characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomised phase III ACT II trial: implications for radiotherapy target volume.

Year:

Session type:

Rob Gynne-Jones1, Helen M Meadows2, Andrew G Renehan3, David Sebag-Montefiore4, Mark Harrison1, Maria Hawkins5, Rebecca Muirhead5, Andre Lopes2, Richard Adams6,
1Mount Vernon Centre for Cancer Treatment, Northwood, London, UK,2Cancer Research UK & University College London Cancer Trials Centre, London, UK,3the Christie NHS Foundation Trust,, Manchester, UK,4St James's Institute of Oncology, Leeds, UK,5The Gray Institute of Radiation Oncology and Biology, Oxford, UK,6Cardiff University and Velindre Cancer Centre, Cardiff, UK

Scheduling nab-Paclitaxel with gemcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-Paclitaxel (NP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC)

Year:

Session type:

Pippa Corrie1, Wendi Qian3, Duncan Jodrell1,2, Si-houy Lao-Sirieix3, Pamela Whittaker3, Aarthi Gopinathan2, Anita Chhabra3, Katy Dalchau3, Bristi Basu1,2, Richard Hardy3, Juan Valle4,
1Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,2Cancer Research UK - Cambridge Institute, University of Cambridge, Cambridge, UK,3Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,4The Christie NHS Foundation Trust, Manchester, UK

Pulmonary Metastasectomy for Colorectal Cancer Metastases in Edinburgh

Year:

Session type:

Archibald Macnair1, Alan Christie1, Ewan Brown1, Hamish Phillips1, Catriona Mclean1, Lesley Dawson1, Sally Clive1, Mark Zahra1,
1Edinburgh Cancer Centre, Edinburgh, UK

Biomarkers for epidermal growth factor receptor (EGFR) inhibitor induced skin toxicity and drug response

Year:

Session type:

Tanusree Paul1, Christian Schumann2, Stefan Rüdiger2, Stefan Boeck3, Volker Heinemann3, Volker Kächele4, Michael Steffens5, Catharina Scholl5, Vivien Hichert5, Thomas Seufferlein4, Julia Carolin Stingl5,6,
1Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany,2Department of Internal Medicine II, University of Ulm, Ulm, Germany,3Department of Internal Medicine III and Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany,4Department of Internal Medicine I, University of Ulm, Ulm, Germany,BfArMResearch Division, Federal Institute of Drugs and Medical Devices,6Faculty of Medicine, University of Bonn, Bonn, Germany

Page 90 of 90« First...25...90